Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 27:13:158.
doi: 10.1186/1471-2407-13-158.

Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

Syed H Jafri  1 , Runhua Shi, Glenn Mills
Affiliations
Review

Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

Syed H Jafri et al. BMC Cancer. .

Abstract

Background: Systemic inflammation has been linked with cancer development, cancer cachexia and poor outcome. Advanced lung cancer inflammation index (ALI) was developed to assess degree of systemic inflammation at the time of diagnosis in metastatic non-small cell lung (NSCLC) cancer patients.

Methods: In a single institution retrospective review 173 patients with metastatic NSCLC diagnosed between Jan 1 2000 and June 30 2011 were included. ALI was calculated as (BMI x Alb / NLR) where BMI = body mass index, Alb = serum albumin, NLR (neutrophil lymphocyte ratio, a marker of systemic inflammation). Patients were divided into low inflammation (ALI ≥ 18) and high inflammation (ALI < 18) groups. Kaplan-Meier method was used to estimate progression free survival and overall survival. Log-rank test were used to compare the survivals among various factors. Multivariate Cox regression was used to perform survival analysis in order to estimate the hazards ratio for various factors.

Results: Among 173 patients median age was 57 years, 67% were male, 52% had adenocarcinoma. Patients with an ALI score of < 18 suggesting high systemic inflammation were significantly more likely to have more than 2 sites of metastatic disease, have poor performance status and less likely to receive any chemotherapy. Their median progression free survival and overall survival was 2.4 months and 3.4 months as opposed to 5.1 months and 8.3 months in patients with ALI >18 (P < 0.001). On multi-variate analysis ALI score of <18 (1.42, 95% CI 1.003-2.01) remained significantly associated with worse outcome.

Conclusion: ALI (<18) at diagnosis is an independent marker of poor outcome in patients with advanced NSCLC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meir survival curve for (PFS) progression free survival and (OS) overall survival between patients with advanced lung cancer inflammation index of (< 18, high inflammation) and (>18, low inflammation). (Time in months).
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62:10–29. doi: 10.3322/caac.20138. - DOI - PubMed
    1. Herbst R, Heymach J, Lippman S. Lung cancer. NEJM. 2008;359:1367–1380. doi: 10.1056/NEJMra0802714. - DOI - PMC - PubMed
    1. Wabah M, Boroumand N, Castro C. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11:89–96. doi: 10.1016/j.anndiagpath.2006.04.006. - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review 1975–2009 (Vintage: Populations) Bethesda, MD: National Cancer Institute; 2009.
    1. Sandler A, Gray R, Perry M. Paclitaxel-carboplatin alone or with bevacizumab in non-small cell lung cancer. NEJM. 2006;355(24):2542–2550. doi: 10.1056/NEJMoa061884. - DOI - PubMed

MeSH terms